Acalabrutinib is a second-generation tyrosine kinase (BTK) inhibitor, a newer drug that can improve the survival of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
The researchers believe that BTK inhibitors combined with modified CD20 antibody drugs (such as Obinutuzumab) can improve the speed and depth of Acalabrutinib treatment by responding to further sensitized cancer cells.
In the Phase 1 b / II clinical trial, the researchers evaluated the effect of the combined therapy of Acalabrutinib and Obinutuzumab at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital-Richard Research Center (OSUCCC-James), convening 45 relapsed / refractory or CLL patients who have never received treatment.
Overall, the combination therapy of Acalabrutinib and Obinutuzumab is well tolerated, and the response rate has improved over time.
Among patients who had not received any treatment, the overall response rate was 95%. The median follow-up period was 17.8 months. The overall survival rate (OS) of patients with relapsed / refractory CLL was 92%, with a median follow-up period of 21 months.
OSUCCC-James. Associate Professor and first author Jennifer Woyach said that despite the progress made in the treatment of CLL in recent years, the need for additional treatment options is still urgent.
The overall effectiveness of the Acalabrutinib trial emphasizes that this clinical study may have a potential impact on the management of CLL.
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
English
Hindi
Bengali
Russian
Arabic
Spanish
French
Afrikaans
Albanian
Amharic
Armenian
Azerbaijani
Bulgarian
Croatian
Czech
Danish
Dutch
Filipino
Finnish
Georgian
German
Greek
Gujarati
Hausa
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Kannada
Kazakh
Khmer
Kyrgyz
Lao
Latin
Latvian
Malay
Malayalam
Mongolian
Myanmar (Burmese)
Norwegian
Persian
Polish
Portuguese
Romanian
Serbian
Shona
Sinhala
Slovak
Slovenian
Somali
Sundanese
Swedish
Tamil
Telugu
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Zulu